Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma
- 28 August 2010
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 457 (4) , 483-495
Abstract
Specific inhibitors targeting the epidermal growth factor receptor (EGFR) can increase survival rates in certain lung adenocarcinoma patients with mutations in the EGFR gene. Although such EGFR-targeted therapies have been approved for use, there is no general consensus among surgical pathologists on how the EGFR status should be tested in lung adenocarcinoma tissues and whether the results of immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and mutational analysis by molecular methods correlate. We evaluated the EGFR status in 61 lung adenocarcinomas by IHC (using total and mutant-specific antibodies against EGFR), by FISH analysis on tissue microarrays (TMAs), and by direct sequencing. The results of each method were compared using χ 2 and κappa statistics. The sensitivity and negative predictive value estimating the presence of abnormal EGFR for each test was calculated. The results show that, with respect to expression patterns and clinicopathological parameters, the total and mutant-specific EGFR detected by immunohistochemistry and FISH analysis on TMAs are valid and are equivalent to conventional methods performed on whole-tissue sections. Abnormal EGFR was detected in 52.4% of patients by IHC, FISH, and sequencing. The best sensitivity (100%) and negative predictive value (100%) was determined by evaluating the EGFR status with all methods. Testing for molecular changes in EGFR using a single test is likely to underestimate the presence of EGFR abnormalities. Taken together, these results demonstrate the high potential of TMAs to test for the major mechanisms of EGFR activation in patients with lung adenocarcinoma.Keywords
This publication has 59 references indexed in Scilit:
- High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancerBritish Journal of Cancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung CancerClinical Cancer Research, 2009
- Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung CancerMolecular & Cellular Proteomics, 2008
- Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor statusBritish Journal of Cancer, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?British Journal of Cancer, 2007
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Tissue microarrays (TMAs) for high-throughput molecular pathology researchInternational Journal of Cancer, 2001
- Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studiesThe Journal of Pathology, 2001